Hormonal contraceptives and arterial thrombosis - Not risk-free but safe enough

New England Journal of Medicine

Volumn 366, Issue 24, 2012, Pages 2316-2318

  Petitti, Diana B ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ESTROGEN; GESTAGEN; GESTODENE; LEVONORGESTREL;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84862225436     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1204769     Document Type: Editorial

References (12)

1. Jordan WM, Anand JK. Pulmonary embolism. Lancet 1961; 278:1146-7.
2. Lorentz IT. Parietal lesion and "Enavid." Br Med J 1962;2:1191.
3. Boyce J, Fawcett JW, Nolan DC. Coronary thrombosis and Conovid. Lancet 1963;281:111.
4. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
5. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
6. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93. (Pubitemid 26001840)
7. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346:1593-6. (Pubitemid 26001841)
8. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, Mac- Rae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8.
9. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66.
10. Ouellet-Hellstrom R, Graham DJ, Staffa JA, et al. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints (http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf).
11. Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011;205:Suppl:S4-S8.
12. Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Saf 2000;22:361-71. (Pubitemid 30261080)